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Abstract We present the first reported crystallization of a 
member of the tbiol-activated family of protein toxins. Per- 
fringolysin 0, a virulence factor of Cfosiridiurn pevfringens, has 
been crystallized in two different forms by the hanging drop 
vapor diffusion method. In one form the toxin crystallizes with 
PEG 20000 in the orth$rhombic sp!ce group C2221_ with cell 
dimensions of a = 47.8 A, b = Hj2.0 A and c = 175.5 A and the 
crystals diffract to beyond 2.5 A resolution. In the second form 
the toxin crystallizes in a large variety of organic solvents 
including malt whisky. This crystal form belongs to the 
orthorhoqbic space g:oup P2221 with0 unit cell dimensions 
a = 47.1 A, b = t66.1 A and c= 214.0 A and with diffraction 
observed to 2.4 A resolution. 
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1. Introduction 
Perfringolysin 0 (PFO; theta toxin) belongs to a large fam- 
ily of membrane-damaging toxins which are produced by four 
genera of Gram-positive bacteria [I]. To date, more than 20 
members have been characterized. This family is generally 
referred to as the oxygen-labile or thiol-activated cytolysins 
because biochemical modification of a key cysteine residue 
causes toxin inactivation, although the cysteine residue itself 
is not essential for toxin function [2,3]. The toxins share a 
common mode of action. In the first step the toxin interacts 
with the target cell membrane via cholesterol which acts as a 
receptor. The thiol-activated cytolysins are the only known 
bacterial toxins that absolutely require cholesterol for their 
activity. The toxin then oligomerizes and partitions into the 
membrane. It is not yet clear whether oligomerization occurs 
before, during or after membrane insertion. The resultant 
membrane-bound oligomers lead to membrane damage and 
eventual cell lysis [l]. The oligomers can be visualized as 
arcs and rings on membranes with an electron microscope 
[4]. The thiol-activated cytolysins are utilized by a wide variety 
of Gram-positive pathogens which exhibit distinct pathogenic 
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traits. It is likely that each of the toxins have diverged to some 
extent to facilitate the pathogenic process of each pathogen. 
PFO is a virulence factor of Clostridium perfringens which 
causes a number of human diseases including gas gangrene, 
food poisoning, necrotizing enterocolitis and enteritis necroti- 
cans [5,6]. The toxin is secreted as a single chain polypeptide 
with a molecular weight of 53 kDa. The gene for PFO has 
been cloned and expressed in E. coli [7]. The nucleotide se- 
quence-derived primary structure shows that PFO consists of 
500 amino acid residues (unpublished results) [8]. The protein 
is water-soluble and it does not possess a hydrophobic se- 
quence long enough to span a membrane. There is nothing 
in its primary structure to explain how the toxin can insert 
into eukaryotic membranes to form ion channels. The pair- 
wise sequence identity between members of the thiol-activated 
cytolysin family is high (40-70%) suggesting they will all have 
very similar three-dimensional structures [l]. 
We have initiated a crystallographic study of PFO as part 
of an on-going study to understand, at the molecular level, 
how proteins insert into or pass through biological mem- 
branes [9,10]. 
2. Material and methods 
2. I. Cloning, expression and puriJication 
The region of the PFO gene encoding residues Lyszg to the end of 
the protein was fused into the BamHI and EcoRI sites of the plasmid 
vector pTrcHisA (termed pRTl0) (Invitrogen). This fusion removed 
the signal peptide coding region from the PFO gene and fused the 
beginning of the coding region of the secreted form of PFO to the 
vector sequence which fused a peptide with the sequence of 
MGGSHHHHHHGMASMTGGQQMGRDLYDDDDKDRWGS 
to Lyszy. Since the signal peptide was replaced, this fusion protein was 
expressed intracellularly in E. roli. The fusion peptide contained a 
polyhistidine region which facilitated the rapid purification of the 
protein using a nickel chelate resin (described below). Most of the 
fusion peptide was removed by cleavage of the fusion protein with 
enterokinase which cleaves on the carboxy terminal side of the 
DDDDK sequence. The sequence DRWGS remains attached to the 
amino terminus of purified PFO after enterokinase cleavage. 
Growth of E. coli strain JM109 containing the vector pRTl0 was 
carried out in the following way for maximum yield of toxin. Two 10 1 
carboys containing 8 1 of terrific broth [Ill were pre-equilibrated at 
37°C and then inoculated 1:33 with an overnight culture of E. coli 
JM109 containing pRTl0. Ampicillin was maintained at 100 @ml in 
both the inoculum culture and carboys. The large cultures were grown 
to an optical density of I at 600 nm and then induced with 1 EM 
IPTG for an additional 4 h. The cultures were continuously aereated 
during the growth of the organism by pumping air into the culture. 
The cells were then separated from the media by centrifugation. The 
cells were lysed by two passages through a French press (20000 psi) 
and the cell debris was removed by centrifugation at 47 000 xg for 30 
min at 5°C. The supernatant (containing the fusion protein) was 
pumped onto a 2.5 X 20 cm column packed with metal chelate Sephar- 
ose (Pharmacia) at 2 ml/min. The column was washed with 100 ml of 
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10 mM MES, pH 6.5, with 150 mM NaCl and 50 mM imidazole. The 
fusion protein was eluted with the same buffer but using 300 mM 
imidazole instead of 50 mM imidazole. The fusion protein was applied 
directly to a column (3.0 x 20 cm) packed with HP Superose SP and 
eluted with a linear gradient of O-80 mM NaCl in 10 mM MES, pH 
6.5. The fusion protein was found to be pure at this point and was 
dialyzed against 10 mM Tris, pH 7.5, containing 1 mM CaClz. The 
fusion protein was then digested with enterokinase at a ratio of 5 U/ 
100 pg of fusion protein for 24 h at room temperature. After digestion 
the amino terminal peptide and any undigested toxin was removed by 
repeating the HP Sepharose SP chromatography. The PFO was then 
dialyzed into 10 mM Tris, pH 8.0, containing 20% glycerol. 
2.2. Crystallization 
In preparation for crystallization, the protein was dialyzed over- 
night against 10 mM Tris-HCI at pH 8.0 and 1 mM DIT. Crystal- 
lization was performed by the hanging drop vapor diffusion method 
[12] using 24-well tissue culture plates. A 2 ~1 droplet containing 7.5 
mg/ml protein was mixed with an equal volume of reservoir solution 
(as described below). Each well contained 1 ml of reservoir solution. 
Initial crystallization trials were performed using a screen similar to 
the one described by Jancarik and Kim [13] and with the crystalliza- 
tion reagent kit, Crystal Screen II, from Hampton Research (Califor- 
nia, USA). The trials were carried out at a constant temperature at 
both 4°C and 22°C. For optimal crystal growth it was later found that 
the total volume of the hanging drop needed to be increased to 10 pl 
and the protein concentration increased to between 15 and 20 mg/ml. 
2.3. Duta collection 
The X-ray diffraction data for crystal form A were collected on the 
beamline 6A2 at the synchrotron radiation source of the Photon Fac- 
tory (Tsukuba, Japan). The wavelength was set to 1.0 A and the data 
were measured at room temperature. The data were collected with 
image plates using the rotation method with 1.5” oscillations. X-ray 
diffraction data for crystal form B were collected using a MARre- 
search imaging plate detector on a Rigaku RU-200 rotating anode 
generator, with graphite-monochromated CuKa radiation (Fig. 1). 
The data were collected at 15°C by the rotation method with oscilla- 
tions of 1 .O”. Determination of unit cell parameters, autoindexing and 
integration of reflection intensities were performed using DENZO [14] 
and the data scaled with SCALEPACK [14]. 
3. Results and discussion 
Our initial crystallization screens resulted in the appearance 
of two different crystal morphologies which we refer to as 
crystal forms A and B. For crystal form A, crystals were 
initially observed after 1 day in 10% (w/v) PEG 20000, 2% 
(v/v) dioxane and 100 mM bicine buffer at pH 9.0. The best 
crystals were grown at 22°C. Without the presence of dioxane, 
the resultant crystals were very small and heavily twinned. 
The best crystals grow as thick plates in 6% (w/v) PEG 
20000, 100 mM bicine buffer at pH 8.7 and 2% (v/v) dioxane. 
The crystals achieve maximum size (up to 0.75 X 0.6 X 0.1 mm) 
within 2 weeks. A native X-ray diffraction data set was col- 
lected using the synchrotron radiation source of the Photon 
Factory (Tsukuba, Japan). We were able to collect a 89% 
complete data set to 2.7 A resolution off a single crystal 
with an RrnerRc of 8.1% (39.2% for the outer shell 2.8 to 2.7 
A). The autoindexing procedure of DENZO [14] indicated 
that the crystals belong to the orthorhombic crystal system, 
with unit cell dimensions of a = 48.8 A, b = 182.0 A and 
c= 175.5 A. Analysis of the various data, including a search 
for systematic absences, showed the data were consistent with 
the space group C2221. The unit cell volume is consistent with 
there being two monomers in the asymmetric unit, yielding a 
specific volume of 1.9 AZ/Da, a value which falls within the 
normal range observed for protein crystals [15]. There are no 
significant peaks in the native Patterson or self-rotation func- 
A 
Fig. 1. Photograph of crystals of perfringolysin 0. A: Crystal form 
A grown from PEG. The largest crystal is 0.6 mm in its longest di- 
mension. B: Crystal form B grown from t-butanol. The largest crys- 
tal is 0.5 mm in its longest dimension. See the text for detailed crys- 
tallization conditions. 
tion map. A preliminary low-resolution electron density map 
based on four heavy atom derivatives demonstrates there is 
only one monomer in the asymmetric unit. 
For crystal form B, crystals were initially observed after 
1 day in 30% (v/v) t-butanol and 100 mM HEPES buffer at 
pH 7.5. In an attempt to improve the crystal size, the nature 
(t-butanol was replaced by ethanol, methanol, n-propanol, 
isopropanol, MPD and various combinations of the above) 
and concentration of the precipitant was varied. There was 
marginal difference in the results obtained by varying the or- 
ganic solvent: indeed t-butanol could be replaced by pure 
malt whisky with ill-effect! Further research in this direction 
is planned! The best crystals grow as thin plates at 22°C in 
20% (v/v) t-butanol, 100 mM HEPES buffer at pH 7.0. The 
crystals achieve maximum size (up to 0.5 X0.2 X0.04 mm) 
within 2 weeks. We were able to collect a 55% complete 
data set in-house to 4.5 A resolution off a single crystal 
with an Rrrlergc of 16.5% (28.7% for the outer shell 4.7 to 
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4.5 A). The quality of the data set was poor due to a combi- 
nation of high crystal mosaicity (> l”), weak diffracting 
power and radiation damage. Nevertheless the data was suffi- 
ciently well-measured to indicate that the crystals belong to 
the orthorhombic crystal system, with unit cell dimensions of 
a=47.5 A, b= 169.4 A and c= 214.6 A. Analysis of the var- 
ious data, including a search for systematic absences, showed 
the data were consistent with the space group P2221. The unit 
cell volume is consistent with there being either three or four 
monomers in the asFetric unit, yielding specific volumes of 
2.7 A3/Da and 2.1 A3/Da, respectively, values which fall with- 
in the normal range observed for protein crystals [15]. We 
have recently discovered that crystals transferred into 15% 
MPD, HEPES buffer pH 7.0 before mounting are significantly 
less mosaic than crystals mounted directly from the crystal- 
lization drop. These crystals diffract to approximately 2.4 A 
resolution using synchrotron radiation and hence represent a 
feasible crystal form for future structural studies. Because the 
organic solvent may mimic the membrane environment the 
toxin encounters on pore formation, we feel work on this 
crystal form is well worth pursuing. 
We have chosen to pursue structural studies on crystal form 
A at this stage since these crystals are much easier to handle 
than crystal form B. We are planning to determine the struc- 
ture of PFO by the standard method of multiple isomorphous 
replacement. We will then solve crystal form B by molecular 
replacement. If necessary we will make use of electron density 
map averaging between the crystal forms to aid in the map 
interpretation. 
We have already obtained a low resolution (6 A) electron 
density map of the toxin from crystal form A. Despite the 
high concentration of protein used in the crystallization trials, 
the toxin appears monomeric. The preliminary map shows the 
toxin to be an elongated molecule with similar dimensions to 
that visualised by electron microscopy [16]. This suggests we 
maybe able to construct the oligomeric membrane form of the 
toxin using a combination of the crystallographic and electron 
microscopic data. 
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